






Supplementary Materials:










Figure S1. Reverse Phase High Performance Liquid Chromatography (RT-HPLC) analysis performed for the purified fractions of the lipopeptides, including (A) C5-CAR, (B) AHX-CAR, (C) C12-CAR, (D) C16-CAR; (E) C5-DK5, (F) AHX-DK5, (G) C12-DK5, (H) C16-DK5, (I) C5-CAR-PEG-DK5, (J) AHX-CAR-PEG-DK5, (K) C12-CAR-PEG-DK5, (L) C16-CAR-PEG-DK5.




Figure S2. CD spectra of the selected lipopeptides obtained in POPG liposome medium.

Inhibition of *S. aureus* biofilm development





Figure S3. Inhibition of *Staphylococcus aureus* biofilm formation by the tested lipopeptides. The antibiofilm activity of the compounds against *S. aureus* (PCM 2054) strain was determined after 24 hours of incubation of the microorganisms in the presence of the selected lipopeptides. The data represents results of MTT assay performed at the end of the experiment. Microbial cell viability within pre-formed biofilms is expressed as the percentage of the cell viability of certain probes with respect to control (microorganisms incubated without peptides). The results were obtained from three independent experiments performed in triplicates and are expressed with standard deviation (error bars).* P < 0.01, **P < 0.005, ***P < 0.0005, ****P < 0.0001 vs. control

Inhibition of *C. albicans* biofilm development




Figure S4. Inhibition of *Candida albicans* biofilm formation by the tested lipopeptides. The antibiofilm activity of the compounds against *C. albicans* (CCM 8186) strain was determined after 24 hours of incubation of the microorganisms in the presence of the selected lipopeptides. The data represents results of MTT assay performed at the end of the experiment. Microbial cell viability within pre-formed biofilms is expressed as the percentage of the cell viability of certain probes with respect to control (microorganisms incubated without peptides). The results were obtained from three independent experiments performed in triplicates and are expressed with standard deviation (error bars). *P < 0.01, **P < 0.005, ***P < 0.0005, ****P < 0.0001 vs. control

Eradication of *S. aureus* pre-formed 24H biofilm





Figure S5. Eradication of the pre-formed 24-hour old biofilm of *S. aureus* after 24-hour treatment with the tested lipopeptides. The antibiofilm activity of the compounds against pre-matured *S. aureus* (PCM 2054) biofilm was determined after 24 hours of incubation of the microorganisms in the presence of the selected lipopeptides. The data represents results of MTT assay performed at the end of the experiment. Microbial cell viability within pre-formed biofilms is expressed as the percentage of the cell viability of certain probes with respect to control (microorganisms incubated without peptides). The results were obtained from three independent experiments performed in triplicates and are expressed with standard deviation (error bars). * $P < 0.01$, ** $P < 0.005$, *** $P < 0.0005$, **** $P < 0.0001$ vs. control

Eradication of *C. albicans* pre-formed 24H biofilm




Figure S6. Eradication of the pre-formed 24-hour old biofilm of *C. albicans* after 24-hour treatment with the tested lipopeptides. The antibiofilm activity of the compounds against pre-matured *C. albicans* (CCM 8186) biofilm was determined after 24 hours of incubation of the microorganisms in the presence of the selected lipopeptides. The data represents results of MTT assay performed at the end of the experiment. Microbial cell viability within pre-formed biofilms is expressed as the percentage of the cell viability of certain probes with respect to control (microorganisms incubated without peptides). The data were obtained from two independent experiments performed in triplicates and are expressed with standard deviation (error bars). * $P < 0.01$, ** $P < 0.005$ vs. control